Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Screening, diagnosis and risks associated with Hepatitis E virus infection
Ist Teil von
Expert review of anti-infective therapy, 2019-06, Vol.17 (6), p.403-418
Ort / Verlag
England: Taylor & Francis
Erscheinungsjahr
2019
Link zum Volltext
Beschreibungen/Notizen
Introduction: Hepatitis E virus (HEV) is the main cause of hepatitis worldwide. Our knowledge of this single-strand positive-sense RNA virus, discovered in the 1980s, has improved greatly in recent years.
Areas covered: We review the most recent information on diagnostic tools, including serological and molecular assays, the recommended diagnostic algorithm, and the clinical manifestations of HEV infections.
Expert opinion: The performance of serological and molecular assays has improved greatly in recent years and the availability of a WHO standard has been invaluable for comparing the performance of molecular assays. The more efficient serological and molecular assays have led to a clearer picture of HEV epidemiology. It is now established that HEV is distributed worldwide. The European Association for the Study of the Liver (EASL) now recommends testing for anti-HEV IgM and HEV RNA. Molecular tests indicate that HEV RNA is very common in asymptomatic blood donors. The description of transfusion-transmitted HEV makes having optimal strategies essential for improving blood safety. Like other hepatitis viruses, HEV infection must be suspected whenever a patient presents with clinical or biochemical features of hepatitis. An HEV infection can also have extra-hepatic manifestations, especially neurological and renal disorders.